CORPORATE PROFILE

Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world's oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies and the company generates more than \$5 billion in annual revenues. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

STOCK PERFORMANCE

BIIB (COMMON STOCK)

Exchange NASDAQ (US Dollar)

Price \$269.45

Change (%)

7.30 (2.78%)

Volume 1,412,021 52 Week Low \$244.28


Market Cap \$57,005,565,743

 Rolling EPS
 14.00

 PE Ratio
 19.2464

 Shares Outstanding
 211,562,686

 Data as of 04/25/18 12:45 p.m. ET



RECENT PRESS RELEASES

04/23/18

New SPINRAZA® (nusinersen) Data Unveiled at AAN Annual Meeting Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for Infants

04/20/18

Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases

04/17/18

Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and Investigational Programs for Neurodegenerative Diseases

03/15/18

Biogen to Present at the 2018 Advances in Alzheimer's and Parkinson's Therapies (AAT-AD/PD) Focus Meeting

03/12/18

New Data Presented at MDA Clinical Conference Show Benefit in Motor Function for Infants, Teens and Young Adults Treated With SPINRAZA® (nusinersen)

ANALYST ESTIMATES / RATINGS

Mean Recommendation: 2.0



UPCOMING EVENTS

There are currently no events scheduled.

RECENT SEC FILINGS

FILING DATE	FORM
04/24/18	10-Q
04/24/18	8-K
03/27/18	PX14A60
03/05/18	4
03/05/18	4

Unable to fulfill request.

Sell Strong Buy

OWNERSHIP SUMMARY

	Holders	Value (\$MM))	% O/S	Shares
Institution	1,576	61,694.24	ŀ	92.0	194,672,555
Mutual Fund	2,719	33,653.65	5	53.4	113,029,725
Insider *	21	58.69)	0.1	202,232
*Insider values reflect direct beneficial ownership.					
		Shares Held	% O/S	Share Change	Filing Date
PRIMECAP Management Company		15,109,231	7.1	-103,683	12/31/17
The Vanguard Group, Inc.		14,871,019	7.0	202,077	12/31/17
BlackRock Institutional Trust Company, N.A.		11,742,836	5.6	-123,981	12/31/17
State Street Global Advisors (US)		9,483,601	4.5	-185,815	12/31/17
ClearBridge Investments, LLC		9,141,651	4.3	-109,176	12/31/17
Fidelity Management & Research Company		8,778,070	4.2	1,769,181	12/31/17
T. Rowe Price Associates, Inc.		8,534,311	4.0	-2,147,067	12/31/17
Wellington Management Company, LLP		5,109,262	2.4	-58,400	12/31/17
AllianceBernstein L.P.		3,426,931	1.6	739,266	12/31/17
Geode Capital Management, L.L.C.		2,443,559	1.2	24,753	12/31/17

Powered By EDGAROnline

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed